Modeling Bronchial Epithelium in Severe Asthma With Human Induced Pluripotent Stem Cells (iPSC)

Inclusion criteria

• ✓. Diagnosis of asthma by the physician for at least 12 months based on the 2019 recommendations of the Global Initiative for Asthma (GINA) group
• ✓. Evidence of hypersensitivity to Aspergillus Fumigatus by skin test (on screening or previous documented positive skin test within the last 12 months), or serum Immunoglobulin E (IgE) specific antibodies to A. Fumigatus (≥ 0.35 kUnit/l) at screening.
• ✓. Elevated total serum IgE (\> 1000 IU/ml). If the 3 ancillary criteria for the diagnosis of of ABPA (below) are met, an IgE level ≤ 1,000 IU/ml is acceptable. If the patient is receiving oral corticosteroids (OCs) at screening, a previous documented IgE level \>1000 IU/ml within the last 12 months is acceptable.
• ✓. Blood eosinophil count \>500 cells/μl at screening for patients not receiving OCs at screening. For patients receiving OCs at screening, blood eosinophil count \> 500 cells/μl at screening or documented previous eosinophil count \> 500 cells/μl in the last 12 months.
• ✓. Presence of precipitating antibodies or serum immunoglobulin G (IgG) to A. Fumigatus at screening.
• ✓. Documented radiological abnormalities consistent with ABPA (such as transient mucoid impaction, hyperdense mucus \[high attenuation of mucous plugs\], opacities of centro-lobular nodules attenuation of mucous plugs\], opacities of centro-lobular nodules, telectasis, bronchiectasis, etc.) by chest X-ray or high-resolution computed tomography (HR-CT) within the last 18 months or at screening.